^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
139MO - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Published date:
11/27/2023
Excerpt:
Adults with previously untreated, HER2-negative, locally advanced, unresectable, or metastatic GC/GEJC...were randomized (1:1) to receive TIS 200 mg...In the ITT population, TIS + chemo showed statistically significant and clinically meaningful improvement in OS vs PBO + chemo and was well tolerated. These data support the TIS + chemo combination as a potential 1L treatment option for pts with advanced GC/GEJC.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Excerpt:
...Pathological immunohistochemistry or FISH detection of gastric cancer tissue indicates negative Her-2; 3....
Trial ID:
Source:
Title:
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
Excerpt:
...Pathologically (histologically or cytologically) confirmed diagnosis of either inoperable, locally advanced or metastatic gastric/GEJ adenocarcinoma that is HER2/neu negative or inoperable, locally advanced or metastatic ESCC....
Trial ID:
